The Rheumatoid Arthritis Drugs Market will register a CAGR of close to 8% by 2022

Tuesday, December 4, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Dec. 3, 2018 /PRNewswire/ -- 107 pagesAbout this marketThe use of biologics and biosimilars for the treatment

of RA is likely to help the market grow. Unlike synthetic DMARDs, biologics have targeted mechanisms of action and serve as promising molecules for the successful treatment of RA. Technavio's analysts have predicted that the rheumatoid arthritis drugs
market will register a CAGR of close to 8% by 2022.Download the full report: https://www.reportbuyer.com/product/5638948 Market OverviewIncreasing need for affordable biologics for rheumatoid arthritisUnlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.Low access to healthcare due to social stigmaSocial stigma associated with RA mainly due to physical deformities and functional limitations in RA patients. Various strategies are being adopted to tackle social stigma at the patient level.For the detailed list of factors that will drive and challenge the growth of the rheumatoid arthritis drugs market during the 2018-2022, view our report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including Amgen and Novartis the competitive environment is quite intense. Factors such as the use of biologics and biosimilars for the treatment of RA and increasing need for affordable biologics for rheumatoid arthritis, will provide considerable growth opportunities to rheumatoid arthritis drugs manufactures. AbbVie, Amgen, Novartis, Pfizer, UCB Pharma, and Johnson & Johnson are some of the major companies covered in this report.'With the presence of a considerable number of companies, this market appears to be fragmented. Many established rheumatoid arthritis drug companies are vying for their share of the global rheumatoid arthritis drugs market, and players must differentiate themselves to gain vital traction over their competitors.'Download the full report: https://www.reportbuyer.com/product/5638948 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-rheumatoid-arthritis-drugs-market-will-register-a-cagr-of-close-to-8-by-2022-300759218.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store